Fatal early onset infection in an extremely low birth weight infant due to Morganella morganii.
OBJECTIVE
This paper reports a case of chorioamnionitis due to Morganella morganii in a mother who presented with ruptured membranes at 24 weeks' gestation and was treated with dexamethasone and prophylactic ampicillin. Her premature infant developed severe early onset infection due to the same organism and expired.


METHODS
A clinical case report of M. morganii infection complicating preterm rupture of membranes is presented. Possible risk factors for maternal and neonatal infection with this organism as well as the therapy of neonatal M. morganii infection are discussed.


RESULTS
Risk factors in the mother included having a cervical cerclage in place and treatment with dexamethasone and prophylactic ampicillin. The major risk factors in the infant were maternal chorioamnionitis and extreme prematurity. The mother responded to treatment with ampicillin, metronidazole, and gentamicin following delivery and had an uncomplicated recovery. Her infant developed severe early onset M. morganii infection complicated by neutropenia, thrombocytopenia, and severe acidosis and expired. Postmortem cultures of pleural fluid, peritoneal fluid, and blood were positive despite treatment with gentamicin, an antibiotic to which the organism was sensitive.


CONCLUSIONS
M. morganii may cause serious infection in pregnancy and in the neonatal period. The use of dexamethasone and prophylactic ampicillin may have increased the risk of infection with this ampicillin-resistant organism. The failure of gentamicin to sterilize the infant's blood and body fluids emphasizes the necessity of treating such infections with a combination of an aminoglycoside and a third-generation cephalosporin, such as cefotaxime.
Ranu
S S
SS
Department of Pediatrics, State University of New York, Health Science Center at Brooklyn, USA.
Valencia
G B
GB
Piecuch
S
S
D000328:Adult; D000667:Ampicillin / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002821:Chorioamnionitis / Q000188:drug therapy; D003907:Dexamethasone / Q000627:therapeutic use; D004756:Enterobacteriaceae Infections / Q000188:drug therapy / Q000635:transmission*; D017809:Fatal Outcome; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000150:complications; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D020613:Morganella morganii / Q000502:physiology; D010403:Penicillin Resistance; D010406:Penicillins / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious
D000893:Anti-Inflammatory Agents; D010406:Penicillins; D000667:Ampicillin; D003907:Dexamethasone